Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors - Scorecard - MDSpire

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors

  • By

  • Viktoria Chirico

  • Niklas Jahn

  • Seyma Büyücek

  • Nina Schraps

  • Maximilian Lennartz

  • Katharina Möller

  • Elena Bady

  • Lisa Hornsteiner

  • Henning Plage

  • Claudia Hube-Magg

  • Martina Kluth

  • Frank Jacobsen

  • Florian Viehweger

  • David Dum

  • Andrea Hinsch

  • Christoph Fraune

  • Christian Bernreuther

  • Patrick Lebok

  • Guido Sauter

  • Till S Clauditz

  • Till Krech

  • Andreas H Marx

  • Ronald Simon

  • Eike Burandt

  • Natalia Gorbokon

  • Sarah Minner

  • Stefan Steurer

  • May 4, 2026

  • 0 min

Share

Clinical Scorecard: Expression of Glutathione Peroxidase 2 in Human Tumors: An Analysis of 18,555 Samples via Tissue Microarray Techniques

At a Glance

CategoryDetail
ConditionCancer with altered GPX2 expression
Key MechanismsRole of GPX2 in removing reactive oxygen species (ROS) and its association with tumor aggressiveness
Target PopulationPatients with various cancer types
Care SettingPathology and oncology departments

Key Highlights

  • GPX2 expression observed in 95 of 148 tumor categories
  • Highest GPX2 positivity in colorectal adenocarcinomas (97.9%) and adenomas (100%)
  • Reduced GPX2 linked to aggressive disease features in colorectal and urothelial carcinomas
  • Low GPX2 expression associated with poor patient outcomes in multiple cancer types
  • Potential prognostic value of GPX2 in various cancers

Guideline-Based Recommendations

Diagnosis

  • Immunohistochemistry for GPX2 expression in tumor samples

Management

  • Consider GPX2 levels in treatment planning and prognostic assessments

Monitoring & Follow-up

  • Regular assessment of GPX2 expression in relation to disease progression

Risks

  • Reduced GPX2 expression may indicate higher risk of aggressive disease and poor outcomes

Patient & Prescribing Data

Patients diagnosed with various cancers, particularly colorectal and urothelial carcinomas

High GPX2 expression may correlate with better treatment responses in certain cancers

Clinical Best Practices

  • Incorporate GPX2 expression analysis in routine pathology assessments
  • Utilize GPX2 as a potential biomarker for cancer prognosis
  • Monitor GPX2 levels in relation to treatment efficacy and disease progression

References

Original Source(s)

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors

  • by Viktoria Chirico, Niklas Jahn, Seyma Büyücek, Nina Schraps, Maximilian Lennartz, Katharina Möller, Elena Bady, Lisa Hornsteiner, Henning Plage, Claudia Hube-Magg, Martina Kluth, Frank Jacobsen, Florian Viehweger, David Dum, Andrea Hinsch, Christoph Fraune, Christian Bernreuther, Patrick Lebok, Guido Sauter, Till S Clauditz, Till Krech, Andreas H Marx, Ronald Simon, Eike Burandt, Natalia Gorbokon, Sarah Minner, Stefan Steurer

  • May 4, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma